Novo Nordisk Launches Once-Weekly Awiqli in the U.S.
Plainsboro, New Jersey, August,11, 2026 Novo Nordisk has announced the nationwide U.S. launch of Awiqli® (insulin icodec-abae) injection 700...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Plainsboro, New Jersey, August,11, 2026 Novo Nordisk has announced the nationwide U.S. launch of Awiqli® (insulin icodec-abae) injection 700...
Bagsværd, Denmark – March 27, 2026 Novo Nordisk announced that the U.S. FDA has approved Awiqli® (insulin icodec-abae), the...
